OM Pharma joins EuropaBio: Transforming Immune Health
PRESS RELEASE
Brussels, 18 November 2024 - EuropaBio is delighted to announce that OM Pharma, a Swiss multinational biotech company has joined its membership.
With nearly a 100-year history, OM Pharma is focussed on transforming immune health using bacterial lysates - medicines which help prime the immune system to prevent infections.
Manufactured from end-to-end on their biotech campus and headquarters in Geneva, lysates have the potential to help address some of today’s most pressing global health challenges including Antimicrobial Resistance (AMR).
Beyond a focus on bacteria-based products, OM Pharma also globally markets small molecules for the treatment of vascular diseases and has a large portfolio of trusted brands in Switzerland and Latin America. OM Pharma products are available in more than 100 countries through a network of trusted partners.
In joining EuropaBio, OM Pharma will bring its expertise as a fully integrated biotech company, covering all areas from API production to commercialisation of finished products in Europe. It seeks to raise the awareness of biotechnology derived therapeutics that protect against and mitigate infectious diseases and reduce the use of antibiotics, while helping to boost the biotechnology & biomanufacturing sector within Europe and beyond.
Dr. Claire Skentelbery, Director General of EuropaBio commented, “OM Pharma is an excellent example of Europe’s capacity within healthcare biotechnology, combining innovation and manufacturing. We are delighted to welcome Christian and the team into EuropaBio at this vital phase of ambition for biotech within policy, and will bring their voices to help turn ambition into the legislation.”
Christian Terreaux, Director Public Affairs for OM Pharma added "With a series of global health challenges looming large, joining forces with EuropaBio helps us become part of a respected community driving for progress in the biotech sector and contributing to policy change for a healthier Europe.”
For more information on OM Pharma, please visit www.ompharma.com